QT-Cab: An Open-Label Study to Investigate the Effect of Cabazitaxel on the QTc Interval in Cancer Patients

Inclusion Criteria

Inclusion criteria:

- Histologically or cytologically confirmed solid malignancy that is metastatic or
unresectable, and for which standard curative measures do not exist, and a treatment
with a novel taxane agent is considered.

Exclusion criteria:

- Conditions with screening ECG repolarization difficult to interpret, or showing
significant abnormalities. This includes, but is not limited to: high degree AV
block, pace-maker, atrial fibrillation or flutter

- QTcF >480 msec on screening Electrocardiogram (ECG)

- Significant hypokalemia at screening (serum potassium <3.5 mMol/L)

- Significant hypomagnesemia at screening (serum magnesium <0.7 mMol/L) (Note: Patient
may be enrolled after correction of these laboratory abnormalities)

- Patient receives (and cannot discontinue), or is scheduled to receive a QT-prolonging
drug

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.